Direct reprogramming induces vascular regeneration post muscle ischemic injury

Area of Science:

• Regenerative Medicine
• Gene Therapy
• Cardiovascular Research

Background:

• Cardiac regeneration is crucial for treating ischemic heart disease.
• Reprogramming non-cardiomyocytes (non-CMs) into cardiomyocyte (CM)-like cells offers a promising therapeutic strategy.
• Existing methods face challenges in efficiency and safety.

Purpose of the Study:

• To evaluate the efficacy of a modified mRNA (modRNA) gene delivery platform for cardiac regeneration.
• To assess the therapeutic potential of a specific modRNA cocktail (7G-modRNA) in a myocardial infarction model.
• To investigate the underlying mechanisms of modRNA-mediated cardiac repair and its broader applicability.

Main Methods:

• Utilized a modified mRNA (modRNA) gene delivery platform to deliver a cocktail of four cardiac-reprogramming genes (Gata4, Mef2c, Tbx5, Hand2) and three helper genes (DN-TGFβ, DN-Wnt8a, acid ceramidase).
• Assessed reprogramming efficiency in vitro and in vivo using a lineage-tracing model in a myocardial infarction setting.
• Analyzed cardiac function, scar size, survival rates, capillary density, and pro-angiogenic marker expression.

Main Results:

• The 7G-modRNA cocktail achieved 57% reprogramming efficiency in vitro.
• In vivo, 7G-modRNA reprogrammed approximately 25% of cells in the scar area post-myocardial infarction.
• Significant improvements were observed in cardiac function, reduced scar size, enhanced long-term survival, and increased capillary density.
• modRNA upregulated pro-angiogenic mesenchymal stromal cell markers and transcription factors, promoting neovascularization in both cardiac and limb ischemia models.
• The study confirmed modRNA as a safe and efficient gene delivery approach without de novo beating CM generation.

Conclusions:

• Modified mRNA (modRNA) gene delivery is a safe and highly efficient platform for inducing cardiomyocyte-like cells.
• 7G-modRNA therapy significantly improves cardiac function and promotes tissue regeneration in ischemic heart disease models.
• The pro-angiogenic effects of modRNA extend beyond cardiac applications, showing potential for treating other ischemic injuries.
• This study validates modRNA technology for therapeutic applications in regenerative medicine, particularly for ischemic diseases.